Heron Therapeutics has been granted a patent for novel pharmaceutical formulations of a neurokinin-1 (NK-1) receptor antagonist suitable for intravenous administration. The formulations, including dexamethasone sodium phosphate, are stable oil-in-water emulsions for non-oral treatment of emesis, particularly beneficial for highly emetogenic cancer chemotherapy. GlobalData’s report on Heron Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Heron Therapeutics, Nanoparticle drug conjugates was a key innovation area identified from patents. Heron Therapeutics's grant share as of January 2024 was 46%. Grant share is based on the ratio of number of grants to total number of patents.
Patent granted for injectable emulsion for preventing post-operative nausea
A recently granted patent (Publication Number: US11878074B2) discloses a method for preventing post-operative nausea and vomiting in a subject by administering an injectable pharmaceutical emulsion. The emulsion comprises a neurokinin-1 (NK-1) receptor antagonist, an emulsifier, an oil, a co-surfactant, and an aqueous phase. The ratio of the emulsifier to the NK-1 receptor antagonist ranges from about 18:1 to 22:1 (wt/wt %), with additional specifications on the ratios of oil to the NK-1 receptor antagonist.
Furthermore, the patent claims include details on the composition of the emulsion, such as the percentage of emulsifier present, the type of emulsifier used (phospholipid), the inclusion of dexamethasone sodium phosphate, and the specific NK-1 receptor antagonists that can be utilized. The method also mentions the use of pH modifiers like oleic acid or buffers, along with specific examples of oils (soybean oil) and alcohols (ethanol) that can be included in the emulsion. Overall, the patent provides a detailed and specific method for preventing post-operative nausea and vomiting in subjects using a carefully formulated injectable pharmaceutical emulsion.
To know more about GlobalData’s detailed insights on Heron Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
